Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
Lumos Pharma (NASDAQ:LUMO) announced the acceptance of an abstract for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (SLEP 2024) in Santiago, Chile. The abstract, titled 'LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials', will be presented as an e-poster on September 13, 2024. This presentation will feature an updated analysis of data from Lumos Pharma's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials, focusing on their therapeutic candidate for rare diseases.
Lumos Pharma (NASDAQ:LUMO) ha annunciato l'accettazione di un abstract per la presentazione al XXXI Meeting della Società Latinoamericana di Endocrinologia Pediatriche (SLEP 2024) a Santiago, in Cile. L'abstract, intitolato 'LUM-201 Ripristina la Segregazione dell'ormone della Crescita e Promuove la Crescita nella Carenza Moderata di Ormone della Crescita Pediatrica (PGHD): Risultati Topline della Fase 2 dagli Studi OraGrowtH210 e OraGrowtH212', sarà presentato come e-poster il 13 settembre 2024. Questa presentazione presenterà un'analisi aggiornata dei dati provenienti dagli studi clinici di Fase 2 OraGrowtH210 e OraGrowtH212 di Lumos Pharma, con un focus sul loro candidato terapeutico per malattie rare.
Lumos Pharma (NASDAQ:LUMO) anunció la aceptación de un resumen para la presentación en el XXXI Encuentro de la Sociedad Latinoamericana de Endocrinología Pediátrica (SLEP 2024) en Santiago, Chile. El resumen, titulado 'LUM-201 Restablece la Secreción de Hormona de Crecimiento y Promueve el Crecimiento en la Deficiencia Moderada de Hormona de Crecimiento Pediátrica (PGHD): Resultados Clave de Fase 2 de los Ensayos OraGrowtH210 y OraGrowtH212', se presentará como un e-poster el 13 de septiembre de 2024. Esta presentación incluirá un análisis actualizado de los datos obtenidos de los ensayos clínicos de Fase 2 OraGrowtH210 y OraGrowtH212 de Lumos Pharma, centrándose en su candidato terapéutico para enfermedades raras.
Lumos Pharma (NASDAQ:LUMO)는 칠레 산티아고에서 열리는 제31회 라틴 아메리카 소아내분비학회(SLEP 2024)에서 발표할 초록의 수락을 발표했습니다. 이 초록의 제목은 'LUM-201이 성장 호르몬 분비를 복원하고 중등도 소아 성장 호르몬 결핍(PGHD)에서 성장을 촉진함: OraGrowtH210과 OraGrowtH212 임상 시험의 2상 주요 결과'이며, 2024년 9월 13일 e-포스터로 발표될 예정입니다. 이 발표에서는 Lumos Pharma의 2상 임상 시험인 OraGrowtH210과 OraGrowtH212의 데이터에 대한 업데이트된 분석이 포함되어 있으며, 희귀 질환을 위한 치료 후보에 초점을 맞추고 있습니다.
Lumos Pharma (NASDAQ:LUMO) a annoncé l'acceptation d'un résumé pour une présentation lors de la XXXIe réunion de la Société Latino-Américaine d'Endocrinologie Pédiatrique (SLEP 2024) à Santiago, au Chili. Le résumé, intitulé 'LUM-201 restaure la sécrétion de l'hormone de croissance et favorise la croissance dans le cas d'une déficience modérée en hormone de croissance pédiatrique (PGHD) : résultats de Phase 2 des études OraGrowtH210 et OraGrowtH212', sera présenté sous la forme d'un e-poster le 13 septembre 2024. Cette présentation inclura une analyse mise à jour des données des essais cliniques de Phase 2 OraGrowtH210 et OraGrowtH212 de Lumos Pharma, se concentrant sur leur candidat thérapeutique pour les maladies rares.
Lumos Pharma (NASDAQ:LUMO) gab die Annahme eines Abstracts für eine Präsentation auf dem XXXI. Treffen der lateinamerikanischen Gesellschaft für pädiatrische Endokrinologie (SLEP 2024) in Santiago, Chile, bekannt. Der Abstract mit dem Titel 'LUM-201 stellt die Sekretion des Wachstumshormons wieder her und fördert das Wachstum bei moderatem pädiatrischen Wachstumshormonmangel (PGHD): Phase-2-Ergebnisse aus den Studien OraGrowtH210 und OraGrowtH212' wird am 13. September 2024 als E-Poster präsentiert. Diese Präsentation wird eine aktualisierte Analyse der Daten aus den Phase-2-Klinischen Studien OraGrowtH210 und OraGrowtH212 von Lumos Pharma bieten, die sich auf ihren therapeutischen Kandidaten für seltene Krankheiten konzentriert.
- Abstract accepted for presentation at a significant medical meeting (SLEP 2024)
- Presentation includes updated analysis of Phase 2 clinical trial data
- Research focuses on LUM-201's potential in treating Pediatric Growth Hormone Deficiency
- None.
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials has been accepted for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (Sociedad Latinoamericana de Endocrinología Pediátrica), or SLEP 2024, to be held September 11-14, 2024 in Santiago, Chile.
Abstract Presentation: Friday, September 13th – E-poster Session 2 – 1:15-2:30PM Local Time
- Abstract entitled, LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials (Rossana Román, MD, et al)
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
What is the title of Lumos Pharma's (LUMO) abstract accepted for SLEP 2024?
When and where will Lumos Pharma (LUMO) present its abstract at SLEP 2024?
What clinical trials are featured in Lumos Pharma's (LUMO) SLEP 2024 presentation?
What is the focus of Lumos Pharma's (LUMO) research presented at SLEP 2024?
